Teva swoops on Auspex with $3.2bn acquisition
This article was originally published in Scrip
Teva Pharmaceutical Industries has agreed to acquire Auspex Pharmaceuticals in an all cash deal valuing the CNS-focused firm at $3.2bn. Teva executives underlined that the deal did not preclude other, bigger, deals that it is still hoping to make.
You may also be interested in...
FDA-approved labeling includes boxed warning for depression and suicidality, though this is specific for Huntington's disease patients, who are prone to these conditions.
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.